Circulating microRNA signature for the diagnosis of very high-risk prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 38, 2016, Pages 10655-10660

  Alhasan, Ali H ^a,b   Scott, Alexander W ^b,c   Wu, Jia J ^a   Feng, Gang ^d   Meeks, Joshua J ^d   Thaxton, C Shad ^a,b,d   Mirkin, Chad A ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Northwestern University   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomarker; microRNA; Prostate cancer; Scano miR; Spherical nucleic acid

Indexed keywords

BIOLOGICAL MARKER; GOLD NANOPARTICLE; MICRORNA; MICRORNA 106A; MICRORNA 135A; MICRORNA 200C; MICRORNA 433; MICRORNA 605; TUMOR MARKER; UNCLASSIFIED DRUG; CIRCULATING MICRORNA; TRANSCRIPTOME;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EXOSOME; GENE EXPRESSION PROFILING; GENETIC IDENTIFICATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMIT OF DETECTION; MALE; MOLECULAR DIAGNOSIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR;

AGED; BIOMARKERS, TUMOR; CIRCULATING MICRORNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RISK FACTORS; TRANSCRIPTOME;

EID: 84988672508     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1611596113     Document Type: Article

References (44)

1. Jemal A, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43-66.
2. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5-29.
3. Heijnsdijk EA, et al. (2009) Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 101(11):1833-1838.
4. Grubb RL, 3rd, et al.; PLCO Project Team (2009) Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 18(3):748-751.
5. Andriole GL, et al.; PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-1319.
6. Crawford ED, Andriole GL, Marberger M, Rittmaster RS (2010) Reduction in the risk of prostate cancer: Future directions after the Prostate Cancer Prevention Trial. Urology 75(3):502-509.
7. Schröder FH, et al.; ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320-1328.
8. Epstein JI (2010) An update of the Gleason grading system. J Urol 183(2):433-440.
9. Hugosson J, et al. (2010) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725-732.
10. Schröder FH, et al.; ERSPC Investigators (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981-990.
11. Conti SL, et al. (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181(4):1628-1633, discussion 1633-1634.
12. Klotz L, et al. (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272-277.
13. Bostwick DG, Myers RP, Oesterling JE (1994) Staging of prostate cancer. Semin Surg Oncol 10(1):60-72.
14. Isariyawongse BK, et al. (2008) Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: The predictive role of age and prostate-specific antigen. Urology 72(4):882-886.
15. Chun FK, et al. (2010) Optimizing performance and interpretation of prostate biopsy: A critical analysis of the literature. Eur Urol 58(6):851-864.
16. Barbieri CE, et al. (2013) The mutational landscape of prostate cancer. Eur Urol 64(4):567-576.
17. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843-854.
18. Lim LP, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433(7027):769-773.
19. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15-20.
20. Mitchell PS, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513-10518.
21. Selth LA, et al. (2012) Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 131(3):652-661.
22. Valadi H, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654-659.
23. Alhasan AH, Patel PC, Choi CHJ, Mirkin CA (2014) Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent microRNA regulation agents. Small 10(1):186-192.
24. Brase JC, et al. (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128(3):608-616.
25. Watahiki A, et al. (2013) Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci 14(4):7757-7770.
26. Grasedieck S, et al. (2013) Circulating microRNAs in hematological diseases: Principles, challenges, and perspectives. Blood 121(25):4977-4984.
27. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ (1996) A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 382(6592):607-609.
28. Taton TA, Mirkin CA, Letsinger RL (2000) Scanometric DNA array detection with nanoparticle probes. Science 289(5485):1757-1760.
29. Alhasan AH, et al. (2012) Scanometric microRNA array profiling of prostate cancer markers using spherical nucleic acid-gold nanoparticle conjugates. Anal Chem 84(9):4153-4160.
30. Kim D, Daniel WL, Mirkin CA (2009) Microarray-based multiplexed scanometric immunoassay for protein cancer markers using gold nanoparticle probes. Anal Chem 81(21):9183-9187.
31. Zeng X, et al. (2012) Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One 7(10):e46367.
32. Dijkstra S, Hamid AR, Leyten GH, Schalken JA (2012) Personalized management in low-risk prostate cancer: The role of biomarkers. Prostate Cancer 2012(327104):327104.
33. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Amer Statist Assn 53(282):457-481.
34. Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18(1):50-60.
35. Volinia S, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257-2261.
36. Huang SP, et al. (2014) Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer 135(11):2661-2667.
37. Sellers WR, Sawyers CA (2002) Somatic genetics of prostate cancer: Oncogenes and tumor suppressors. Prostate Cancer: Principles and Practice, ed Kantoff PW (Lippincott Williams & Wilkins, Philadelphia, PA), 1st Ed, pp 53-76.
38. Majumder PK, Sellers WR (2005) Akt-regulated pathways in prostate cancer. Oncogene 24(50):7465-7474.
39. Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24(50):7443-7454.
40. Marques RB, et al. (2015) High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. Eur Urol 67(6):1177-1185.
41. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100(16):9440-9445.
42. Reczko M, Maragkakis M, Alexiou P, Grosse I, Hatzigeorgiou AG (2012) Functional microRNA targets in protein coding sequences. Bioinformatics 28(6):771-776.
43. Vlachos IS, et al. (2015) DIANA-TarBase v7.0: Indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res 43(Database Issue):D153-D159.
44. Vlachos IS, et al. (2012) DIANA Mirpath V.2.0: Investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 40(Web Server Issue):W498-W504.